Janssen presents new real-world evidence at the Annual European Congress of Rheumatology (EULAR 2019) which suggests that effective PsA treatment should target more than skin and joints


MADRID–(BUSINESS WIRE)–The Janssen Pharmaceutical Companies of Johnson & Johnson presented new data this week from PsABio – its ongoing, real-world study of nearly 1,000 people with psoriatic arthritis, who have started treatment with either Stelara (ustekinumab) or a Tumour Necrosis Factor inhibitor (TNFi).1 This important data was presented at this year’s Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain. PsA is a challenging and multi-faceted immune-mediated inflam http://www.businesswire.com/news/home/20190613005251/en/Janssen-presents-new-real-world-evidence-Annual-European/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==